Moderna (MRNA) Stock Price, News & Analysis

Company Overview

Moderna, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions. Beyond COVID-19, the company is developing vaccines targeting influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV) and Zika virus, as well as combination vaccines designed to protect against multiple respiratory pathogens. In addition to vaccines, Moderna is exploring mRNA therapeutics for oncology, rare diseases and cardiovascular conditions, leveraging partnerships with academic institutions and government agencies to accelerate development.

The company was co-founded by a team of scientists and backed by Flagship Pioneering. Stéphane Bancel joined as chief executive officer in 2011 and has overseen Moderna’s rapid growth from a research-stage enterprise to a globally recognized biopharmaceutical company. Under his leadership, Moderna established large-scale manufacturing capabilities and forged collaborations with public health bodies such as the Biomedical Advanced Research and Development Authority (BARDA) in the United States and the Coalition for Epidemic Preparedness Innovations (CEPI).

Moderna’s operations extend worldwide, with regional offices across North America, Europe and Asia-Pacific, and manufacturing facilities in the United States and Europe. The company continues to expand its global footprint through strategic alliances, technology transfer agreements and participation in international vaccine distribution initiatives. As it advances its mRNA platform, Moderna aims to build a diversified portfolio of products to address both emerging and longstanding public health challenges.

Key Stats

• Today's Range: $46.48 to $47.93
• 50-Day Range: $45.72 to $55.97
• 52-Week Range: $22.28 to $59.55
• Volume: 4.78 million shs
• Average Volume: 8.03 million shs
• Market Capitalization: $18.75 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.73
• Consensus Rating: Reduce

Moderna Stock Analysis - MarketRank™

Moderna scored higher than 28% of companies evaluated by MarketBeat, and ranked 761st out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Moderna has received a consensus rating of Reduce. The company's average rating score is 1.84, and is based on no strong buy ratings, 2 buy ratings, 12 hold ratings, and 5 sell ratings.

Downside Risk

Moderna has a consensus price target of $35.73, representing about 24.4% downside from its current price of $47.26.

Amount of Analyst Coverage

Moderna has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Moderna are expected to grow in the coming year, from ($6.76) to ($4.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Moderna is -5.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Moderna is -5.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Moderna has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.47% of the float of Moderna has been sold short.

Short Interest Ratio / Days to Cover

Moderna has a short interest ratio ("days to cover") of 10.15, which indicates bearish sentiment.

Change versus previous month

Short interest in Moderna has recently decreased by 1.90%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Moderna does not currently pay a dividend.

Dividend Growth

Moderna does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.01

News Sentiment

Moderna has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Moderna this week, compared to 10 articles on an average week.

Search Interest

50 people have searched for MRNA on MarketBeat in the last 30 days. This is an increase of 32% compared to the previous 30 days.

MarketBeat Follows

13 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is an increase of 86% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Moderna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,661,254.00 in company stock.

Percentage Held by Insiders

10.80% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.33% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/01/2026
• Today: 5/22/2026
• Bernstein 42nd Annual Strategic Decisions Conference: 5/28/2026
• Status update: 6/25/2026
• Next Earnings (Estimated): 7/31/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRNA
• CIK: 1682852
• Web: www.modernatx.com
• Phone: (617) 714-6500
• Fax: N/A
• Employees: 4,700
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Moderna: $35.73
• High Price Target: $69.00
• Low Price Target: $17.00
• Potential Upside/Downside: -24.4%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.84
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.82 billion
• Net Margins: -143.55%
• Pretax Margin: -141.03%
• Return on Equity: -26.64%
• Return on Assets: -19.32%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 2.41
• Quick Ratio: 2.35

Sales & Book Value

• Annual Sales: $1.94 billion
• Price / Sales: 9.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $18.67 per share
• Price / Book: 2.53

Miscellaneous

• Outstanding Shares: 396,790,000
• Free Float: 353,933,000
• Market Cap: $18.75 billion
• Optionable: Optionable
• Beta: 1.05